ArticleO&G open2025
Changes in Low-Dose Aspirin Use After Updated Guidance on Sociodemographic Risk Factors for Preeclampsia.
Article in O&G open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Low-Dose Aspirin Recommendations for Preeclampsia Risk Reduction: A Systematic Review Focused on Black Patients : Current Hypertension Reports.Current hypertension reports · 2026Pooled it
- Budget Impact Model of a Novel cfRNA Test-and-Treat Strategy for Preeclampsia in Advanced Maternal Age Pregnancies Compared with Current Guidelines.PharmacoEconomics - open · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo assess whether the modifications to the U.S. Preventive Services Task Force (USPSTF) and American College of Obstetricians and Gynecologists (ACOG) guidelines that emphasize "lower income" status and Black racial identity (as a proxy for underlying systemic racism) as moderate risk factors for preeclampsia were associated with increased low-dose aspirin use in these groups.
methodsWe performed a repeated cross-sectional analysis of nulliparous patients who delivered at 24 weeks of gestation or later from 2017 to 2022 within one health care system with an indication for low-dose aspirin use during the pregnancy. Two cohorts were created, with patients matched exactly on other known risk factors for preeclampsia. The first cohort was stratified by Black and White race; the second cohort was stratified by Medicaid insurance (as a proxy for lower income) and private insurance. Two patient-level difference-in-difference analyses were performed in each matched cohort using linear regression. The
resultsThe study included 31,555 participants: 11,612 in the first cohort examining race and 14,208 in the second cohort examining lower income. In the first cohort, 2,614 patients (22.5%) were matched; in the second cohort, 3,602 patients (22.6%) were matched. The rate of low-dose aspirin use among patients who self-identified as Black increased by 8.8 percentage points (95% CI, 0.076-16.9) relative to those who identified as White. The rate of low-dose aspirin use among patients with Medicaid insurance did not increase relative to those with private insurance (difference-in-difference estimate -1.1 percentage points; 95% CI, -9.3 to 7.2).
conclusionNew guidelines from the USPSTF and ACOG in 2021 that emphasized the racial inequities of preeclampsia were associated with an increase in the rate of low-dose aspirin use in Black patients but not in patients with public insurance. Despite new guidance, overall rates of low-dose aspirin use remain well below expected based on what is recommended by professional organizations.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.